Stavudine
- Generic Name
- Stavudine
- Brand Names
- Zerit
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12N2O4
- CAS Number
- 3056-17-5
- Unique Ingredient Identifier
- BO9LE4QFZF
- Background
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
- Indication
For the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- Human Immunodeficiency Virus (HIV) Infections
- Associated Therapies
- -
Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 198
- Registration Number
- NCT00000851
- Locations
- 🇺🇸
Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States
🇺🇸St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States
🇺🇸Cook County Hosp., Chicago, Illinois, United States
Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-28
- Target Recruit Count
- 24
- Registration Number
- NCT00000901
- Locations
- 🇺🇸
UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States
🇺🇸Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States
🇺🇸Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States
A Study of HIV-Disease Development in Aging
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00006144
- Locations
- 🇺🇸
Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸Mt. Sinai Med. Ctr. A0404 CRS, New York, New York, United States
🇺🇸Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States
Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 121
- Registration Number
- NCT00000940
- Locations
- 🇺🇸
SSTAR, Family Healthcare Ctr., Fall River, Massachusetts, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
🇺🇸USC CRS, Los Angeles, California, United States
The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 300
- Registration Number
- NCT00001087
- Locations
- 🇺🇸
Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 100
- Registration Number
- NCT00004578
- Locations
- 🇺🇸
Northwestern University Medical School, Chicago, Illinois, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002369
- Locations
- 🇵🇷
San Juan AIDS Program, Santurce, Puerto Rico
🇺🇸Boston Univ Med Ctr Hosp / Evans - 556, Boston, Massachusetts, United States
🇺🇸HIV Clinical Research Ctr, Fort Lauderdale, Florida, United States
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2007-10-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 200
- Registration Number
- NCT00002168
- Locations
- 🇺🇸
Univ of Nebraska, Omaha, Nebraska, United States
🇺🇸Anderson Clinical Research, Washington, District of Columbia, United States
🇵🇷Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 24
- Registration Number
- NCT00000896
- Locations
- 🇺🇸
Ucsd, Avrc Crs, San Diego, California, United States
🇺🇸University of Colorado Hospital CRS, Aurora, Colorado, United States
🇺🇸Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-11
- Target Recruit Count
- 44
- Registration Number
- NCT00004736
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.